EVOKE-3
14 Sep 2023
EVOKE-03
NCT05609968
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
Merck Sharp & Dohme LLC
Cancer Type | Carcinoma, Non-Small-Cell Lung |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 Years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | - |
Anticipated Start Date | 2023-02-06 |
Anticipated End Date | 2028-08-23 |
Hospital | Cancer Research SA |
---|---|
Clinical Trial Coordinator | Kelly Mead/Kate Penta |
admin@cancerresearchsa.com.au | |
Phone | 08 8359 2565 |
Principal Investigator | Rohit Joshi |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs